- Home
- GLMD vs PMCB Comparison
GLMD vs PMCB Comparison
Compare GLMD & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- PMCB
- Stock Information
- Founded
- GLMD 2000
- PMCB 1996
- Country
- GLMD Israel
- PMCB United States
- Employees
- GLMD N/A
- PMCB N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLMD Health Care
- PMCB Health Care
- Exchange
- GLMD Nasdaq
- PMCB Nasdaq
- Market Cap
- GLMD 6.6M
- PMCB 6.6M
- IPO Year
- GLMD 2014
- PMCB N/A
- Fundamental
- Price
- GLMD $1.18
- PMCB $0.87
- Analyst Decision
- GLMD Hold
- PMCB
- Analyst Count
- GLMD 1
- PMCB 0
- Target Price
- GLMD N/A
- PMCB N/A
- AVG Volume (30 Days)
- GLMD 65.7K
- PMCB 41.1K
- Earning Date
- GLMD 11-14-2025
- PMCB 12-12-2025
- Dividend Yield
- GLMD N/A
- PMCB N/A
- EPS Growth
- GLMD N/A
- PMCB N/A
- EPS
- GLMD N/A
- PMCB 0.01
- Revenue
- GLMD N/A
- PMCB N/A
- Revenue This Year
- GLMD N/A
- PMCB N/A
- Revenue Next Year
- GLMD N/A
- PMCB N/A
- P/E Ratio
- GLMD N/A
- PMCB $139.50
- Revenue Growth
- GLMD N/A
- PMCB N/A
- 52 Week Low
- GLMD $1.15
- PMCB $0.79
- 52 Week High
- GLMD $3.61
- PMCB $1.94
- Technical
- Relative Strength Index (RSI)
- GLMD 32.65
- PMCB 35.21
- Support Level
- GLMD $1.16
- PMCB $0.79
- Resistance Level
- GLMD $1.27
- PMCB $0.93
- Average True Range (ATR)
- GLMD 0.08
- PMCB 0.05
- MACD
- GLMD -0.02
- PMCB -0.01
- Stochastic Oscillator
- GLMD 0.00
- PMCB 25.59
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.